Less than 1 min.Read

Imugene: Receives clinical guidance from U.S. FDA for VAXinia

August 6, 2020

Imugene has received guidance from the U.S. Food and Drug Administration (FDA) for the development of VAXinia
The FDA provided guidance on a development plan for a phase one study design as well as feedback on part two of the study
VAXinia is an oncolytic virotherapy drug that is being developed to treat various cancers
Given the uncertainty during the COVID-19 pandemic, Imugene considers it important to be flexible with identifying regulatory pathways
Imugene is also seeking a regulatory pathway in Australia
Company shares are up 2.68 per cent and are trading for 5.8 cents